Form 4: CRISPR CFO Reports RSU Vesting, Tax Sales, and Gift

CRISPR Therapeutics CFO Raju Prasad reported the vesting of restricted stock units, subsequent sales to cover tax obligations, and a gift of common shares.

Summary

• Raju Prasad, Chief Financial Officer of CRISPR Therapeutics AG (CRSP), reported transactions involving common shares.
• On March 14, 2026, 10,000 common shares vested from a Restricted Stock Unit (RSU) award granted on March 14, 2023.
• Also on March 14, 2026, an additional 6,875 common shares vested from an RSU award granted on March 14, 2025.
• On March 16, 2026, Prasad sold 5,848 common shares at $48.26 per share to cover tax withholding obligations related to the RSU vesting.
• An additional 4,021 common shares were sold on March 16, 2026, at $48.26 per share for tax withholding purposes.
• On March 16, 2026, Prasad gifted 750 common shares at a price of $0.00 per share.
• Following these transactions, Prasad beneficially owns 13,023 direct common shares.
• Prasad also holds 10,000 Restricted Stock Units from the March 14, 2023 grant and 20,625 Restricted Stock Units from the March 14, 2025 grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine insider transactions related to executive compensation and tax obligations, which typically do not indicate a change in company fundamentals or strategic direction.

Positives

• The vesting of Restricted Stock Units indicates ongoing compensation and retention of a key executive.

Negatives

• Sales of common shares occurred, but these were mandated to cover tax withholding obligations and not discretionary trades.

Future Outlook

Future vesting schedules for Restricted Stock Units are outlined, with remaining portions of the March 14, 2023 grant vesting on March 14, 2027, and remaining portions of the March 14, 2025 grant vesting annually on March 14 through 2029.

Management Comments

• The amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units.
• This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that insider transaction reports like this Form 4 are standard disclosures in the biotechnology sector, reflecting executive compensation structures that often include equity awards. While specific to CRISPR Therapeutics, the mechanism of RSU vesting and subsequent tax-related sales is common across publicly traded companies, particularly in high-growth industries where equity compensation is a significant component of executive pay.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine insider transactions related to compensation and tax obligations, not a discretionary sale indicating a change in confidence.
• Employees: Reflects standard equity compensation practices for executives.

Next Steps

• Remaining portions of the March 14, 2023 RSU award are scheduled to vest on March 14, 2027.
• Remaining portions of the March 14, 2025 RSU award are scheduled to vest annually on March 14, 2027, March 14, 2028, and March 14, 2029.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Common Shares, Biotechnology, Gene Editing